BioSpace News Archive

Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA).

Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced that it has received two notices of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, JATENZO® (testosterone undecanoate).

The third calendar quarter of 2021 financial results continued to demonstrate Utah Medical Products, Inc.’s recovery after a time when there were restrictions on so-called nonessential medical procedures during the COVID-19 pandemic.

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), a growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announces today that CEO Donal Schmidt will present a corporate overview at the Benzinga Global Small Cap Conference.

Aidoc, the leading provider of AI for medical imaging, and ScreenPoint Medical, leader of deep learning AI for 2D and 3D mammography, today announced a collaboration which will incorporate ScreenPoint’s capabilities into Aidoc’s platform

Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing and intensity of treatment in men experiencing prostate cancer progression following radical prostatectomy.

Ortek announced the widespread availability of its ECD device, which provides dental professionals a new diagnostic tool for the early detection of cavities that are often not picked up by X-rays.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021, after market close.

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, November 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2021.